David P Bender, MD
Professor of Obstetrics and Gynecology, Division of Gynecologic Oncology
Primary Office
Current Positions
- Professor of Obstetrics and Gynecology - Division of Gynecologic Oncology
- Medical Director of Robotic Surgery
- NRG Oncology Principal Investigator
Education
- BA, Bowdoin College, Brunswick, Maine
- MD in Medicine, Finch University of the Health Sciences/The Chicago Medical School, North Chicago, Illinois
- Resident in Obstetrics and Gynecology & Reproductive Sciences, Magee-Women's Hospital, University Health Center of Pittsburgh, Pittsburgh, Pennsylvania
- Fellow and Lecturer in Department of OB/GYN, University of Louisville School of Medicine, Louisville, Kentucky
- Fellow Associate in Gynecologic Surgery, University of Iowa Hospitals and Clinics, Iowa City, Iowa
- Fellow in Gynecologic Oncology, University of Iowa Hospitals and Clinics, Iowa City, Iowa
Research Interests
- Minimally Invasive Surgery in Gynecologic Oncology Using Robotic-Assisted Laparoscopy. University of Iowa Hospitals and Clinics, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, November 2005 – Present
- Evaluation of Combined Chemotherapy and Radiation Therapy for the Treatment of Clear Cell and Serous Uterine Carcinoma in Conjunction with Pharmacogenomic Analysis for Clinical Outcomes and Risk of Thrombosis, January 2007-Present
- The Immune Response in the Neoplastic Cervix during Pregnancy. Magee-Womens Hospital/University Health Center of Pittsburgh, 1998-1999
- Excited State Reactions between a Platinum (II) Dimer and Lead (II), Tin (II), Indium (III), Gallium (III), and Thallium (I). Under the direction of Jeffrey K. Nagle, Ph.D. Bowdoin College, Brunswick, Maine, 1989-1991
- Bender, DP, MacKay H, Rimel BJ, A four arm randomized Phase II study comparing single agent olaparib, single agent cediranib, olaparib/cediranib, or olaparib, AZD 1775 (Wee-1 inhibitor) in women with recurrent or persistent endometrial cancer. 2016 – Present
- Bender DP, Leslie KK, et al, Targeted Therapy in Advanced/Recurrent Endometrial Cancer, 2010 – Present.
- Bender DP, Leslie KK, et al, Cediranib Therapy In Recurrent/Persistent Endometrial Cancer, 2010 – Present
- X-chromosome inactivation in gynecologic malignancies University of Iowa Hospitals and Clinics, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, July 2001 – Present
- Prognostic Significance of Serologic markers in Ovarian Cancer. University of Iowa Hospitals and Clinics, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, July 2000 – Present
- Modulation of T-Cell Receptor Zeta Chain Expression in Pregnancy and in Patients with Gynecologic Malignancies. University of Louisville School of Medicine, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, July 1999 – June 2000
Licenses & Certifications
- Subspecialty Certification in Gynecologic Oncology
- Board Certification in Obstetrics & Gynecology
- Iowa Medical License #33545, Iowa
Selected Publications
- Gonzalez Bosquet J, Wagner V, Polio A, Linder KE, Bender DP, Goodheart MJ, Schickling BM. Identification of Ovarian High-Grade Serous Carcinoma with Mitochondrial Gene Variation. Int J Mol Sci. 2025 Feb 5;26(3):1347. doi: 10.3390/ijms26031347. PMID: 39941116; PMCID: PMC11818617. https://www.mdpi.com/1422-0067/26/3/1347
- Auranen A, Powell MA, Sukhin V, Landrum LM, Ronzino G, Buscema J, Bauerschlag D, Lalisang R, Bender D, Gilbert L, Armstrong A, Safra T, Nevadunsky N, Sebastianelli A, Slomovitz B, Ring K, Coleman R, Podzielinski I, Stuckey A, Teneriello M, Gill S, Pothuri B, Willmott L, Sharma S, Dabrowski C, Antony G, Stevens S, Mirza MR, Fleming E. Safety of dostarlimab in combination with chemotherapy in patients with primary advanced or recurrent endometrial cancer in a phase III, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY). Ther Adv Med Oncol. 2024 Sep 28;16:17588359241277656. doi: 10.1177/17588359241277656. PMID: 39346117; PMCID: PMC11439170. https://journals.sagepub.com/doi/10.1177/17588359241277656
- Brown J, Miller A, Holman LL, Backes F, Nagel C, Bender D, Miller DS, Powell MA, Westin SN, Bonebrake A, Muller CY, Secord AA, Crane E, Schorge J, Tew WP, Sood AK, Bookman MA, Aghajanian C, Gershenson DM. Results of a randomized phase II trial of paclitaxel and carboplatin versus bleomycin, etoposide and cisplatin for newly diagnosed and recurrent Chemonaive stromal ovarian tumors: An NRG oncology/gynecologic oncology group study14. Gynecol Oncol. 2024 Nov;190:283-290. doi: 10.1016/j.ygyno.2024.09.002. Epub 2024 Sep 12. PMID: 39265466. https://www.sciencedirect.com/science/article/pii/S0090825824011090?via%3Dihub
- Mirza MR, Chase DM, Slomovitz BM, dePont Christensen R, Novák Z, Black D, Gilbert L, Sharma S, Valabrega G, Landrum LM, Hanker LC, Stuckey A, Boere I, Gold MA, Auranen A, Pothuri B, Cibula D, McCourt C, Raspagliesi F, Shahin MS, Gill SE, Monk BJ, Buscema J, Herzog TJ, Copeland LJ, Tian M, He Z, Stevens S, Zografos E, Coleman RL, Powell MA; RUBY Investigators. Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer. N Engl J Med. 2023 Jun 8;388(23):2145-2158. doi: 10.1056/NEJMoa2216334. Epub 2023 Mar 27. PMID: 36972026.
- Klopp AH, Enserro D, Powell M, Randall M, Schink JC, Mannel RS, Holman L, Bender D, Kushnir CL, Backes F, Zweizig SL, Waggoner S, Bradley KA, Lawrence LD, Hanjani P, Darus CJ, Small W Jr, Cardenes HR, Feddock JM, Miller DS. Radiation Therapy With or Without Cisplatin for Local Recurrences of Endometrial Cancer: Results From an NRG Oncology/GOG Prospective Randomized Multicenter Clinical Trial. J Clin Oncol. 2024 Jul 10;42(20):2425-2435. doi: 10.1200/JCO.23.01279. Epub 2024 Apr 25. PMID: 38662968; PMCID: PMC11681946. https://ascopubs.org/doi/10.1200/JCO.23.01279
- Pothuri B, Han S, Chase DM, Heitz F, Burger RA, Gaba L, Van Le L, Guerra E, Bender D, Korach J, Cloven N, Churruca C, Follana P, DiSilvestro P, Baurain JF, Jardon K, Pisano C, Peen U, Mäenpää J, Gupta D, Bacqué E, Li Y, Compton N, Antonova J, Monk BJ, González-Martín A. Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial. Gynecol Oncol. 2024 May;184:168-177. doi: 10.1016/j.ygyno.2024.01.021. Epub 2024 Feb 6. PMID: 38325276.
- Rimel BJ, Enserro D, Bender DP, Jackson CG, Tan A, Alluri N, Borowsky M, Moroney J, Hendrickson AW, Backes F, Swisher E, Powell M, MacKay H. NRG-GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer. Cancer. 2024 Apr 15;130(8):1234-1245. doi: 10.1002/cncr.35151. Epub 2023 Dec 21. PMID: 38127487; PMCID: PMC11168450.
- Sia TY, Tew WP, Purdy C, Chi DS, Menzin AW, Lovecchio JL, Bookman MA, Cohn DE, Teoh DG, Friedlander M, Bender D, Mutch DG, Gershenson DM, Tewari KS, Wenham RM, Wahner Hendrickson AE, Lee RB, Gray HJ, Secord AA, Van Le L, Lichtman SM. The effect of older age on treatment outcomes in women with advanced ovarian cancer receiving chemotherapy: An NRG-Oncology/Gynecologic Oncology Group (GOG-0182-ICON5) ancillary study. Gynecol Oncol. 2023 Jun;173:130-137. doi: 10.1016/j.ygyno.2023.03.018. Epub 2023 May 4. PMID: 37148580.
- Gonzalez-Bosquet J, Gabrilovich S, McDonald ME, Smith BJ, Leslie KK, Bender DP, Goodheart MJ, Devor E. Integration of Genomic and Clinical Retrospective Data to Predict Endometrioid Endometrial Cancer Recurrence. Int J Mol Sci. 2022 Dec 16;23(24):16014. doi: 10.3390/ijms232416014. PMID: 36555654; PMCID: PMC9785370.
- Gonzalez-Bosquet J, Cardillo ND, Reyes HD, Smith BJ, Leslie KK, Bender DP, Goodheart MJ, Devor EJ. Using Genomic Variation to Distinguish Ovarian High-Grade Serous Carcinoma from Benign Fallopian Tubes. Int J Mol Sci. 2022 Nov 26;23(23):14814. doi: 10.3390/ijms232314814. PMID: 36499142; PMCID: PMC9738935.